Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer

Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease

Related Keywords

France ,French ,Phil Febbo ,Jean Perrin ,Pascal Pujol ,Toulouse Oncopole ,Research Use ,Prnewswire Illumina Inc ,French Society For Predictive ,Clermont Ferrand University Hospital ,Jean Perrin Center ,Nasdaq ,Bordeaux University Hospital Center ,Chief Medical Officer ,General Director ,Professor Pascal Pujol ,French Society ,Personalized Medicine ,Oncogenetics Department ,Montpellier University ,One Genomics ,Trusight Oncology ,Research Use Only ,Comprehensive Genomic Profiling ,Tumor Mutational Burden ,Microsatellite Instability ,Cancer ,Illumina ,Medicine ,Precision Medicine ,Essay ,Biopsy ,Cancer Therapy ,Olorectal ,Na ,Gene ,Genes ,Enomic ,Healthcare ,Hospital ,Lung Cancer ,Melanoma ,Ncology ,Research ,Humor ,